These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21860366)

  • 1. Rivaroxaban (Xarelto)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
    [No Abstract]   [Full Text] [Related]  

  • 2. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
    Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):218. PubMed ID: 21881694
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
    Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral Rivaroxaban (Xarelto)].
    Peeters S; Warnez M
    J Pharm Belg; 2013 Mar; (1):37-40. PubMed ID: 23638611
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban, the first oral, direct factor Xa inhibitor.
    Fassiadis N
    Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rivaroxaban: Xarelto--recommendations for pharmacists].
    Douxfils J; Michel S; Beauloye C; Goethals M; Hainaut P; Heidbuchel H; Hermans C; Ickx B; Jochmans K; Mottes S; Mullier F; Peeters A; Scavée C; Sinnaeve P; Sprynger M; Thijs V; Vandenbroeck C; Vandermeulen E; Verhamme P; Dogné JM
    J Pharm Belg; 2013 Mar; (1):28-36. PubMed ID: 23638610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for thromboprophylaxis.
    Lotke PA
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
    Ageno W
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
    Kakar P; Watson T; Lip GY
    Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Summary and perspectives. Rivaroxaban].
    Albaladejo P
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of rivaroxaban-treated patients.
    Palareti G; Ageno W; Ferrari A; Filippi A; Imberti D; Pengo V; Rubboli A; Toni D
    Expert Opin Pharmacother; 2013 Apr; 14(5):655-67. PubMed ID: 23414291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
    Lee S; White CM
    Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.